$VCNX
VACCINEX, INC.

2021 Q3 Form 10-Q Financial Statement

#000156459021055065 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2020 Q3
Revenue $50.00K $630.0K
YoY Change -92.06% 55.94%
Cost Of Revenue $2.000K
YoY Change -75.0%
Gross Profit $620.0K
YoY Change 56.57%
Gross Profit Margin 98.41%
Selling, General & Admin $1.484M $1.870M
YoY Change -20.64% 22.22%
% of Gross Profit 301.61%
Research & Development $3.629M $7.334M
YoY Change -50.52% 12.09%
% of Gross Profit 1182.9%
Depreciation & Amortization $37.00K $74.00K
YoY Change -50.0% 15.63%
% of Gross Profit 11.94%
Operating Expenses $5.113M $7.334M
YoY Change -30.28% 12.09%
Operating Profit -$5.063M -$8.583M
YoY Change -41.01% 11.79%
Interest Expense $142.0K $148.0K
YoY Change -4.05%
% of Operating Profit
Other Income/Expense, Net -$1.000K -$23.00K
YoY Change -95.65% -163.89%
Pretax Income -$5.206M -$8.754M
YoY Change -40.53% 14.55%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.206M -$8.754M
YoY Change -40.53% 14.55%
Net Earnings / Revenue -10412.0% -1389.52%
Basic Earnings Per Share -$0.17
Diluted Earnings Per Share -$169.0K -$436.0K
COMMON SHARES
Basic Shares Outstanding 30.80M
Diluted Shares Outstanding 30.80M

Balance Sheet

Concept 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.74M $17.09M
YoY Change -19.6% 99.18%
Cash & Equivalents $13.74M $17.09M
Short-Term Investments
Other Short-Term Assets $1.071M $700.0K
YoY Change 53.0% 9.38%
Inventory
Prepaid Expenses
Receivables $50.00K $443.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $14.86M $18.24M
YoY Change -18.51% 76.89%
LONG-TERM ASSETS
Property, Plant & Equipment $327.0K $488.0K
YoY Change -32.99% -2.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $327.0K $493.0K
YoY Change -33.67% -1.4%
TOTAL ASSETS
Total Short-Term Assets $14.86M $18.24M
Total Long-Term Assets $327.0K $493.0K
Total Assets $15.19M $18.73M
YoY Change -18.91% 73.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $957.0K $2.940M
YoY Change -67.45% 25.64%
Accrued Expenses $1.208M $2.990M
YoY Change -59.6% -34.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $7.890M
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.165M $13.83M
YoY Change -84.34% 100.39%
LONG-TERM LIABILITIES
Long-Term Debt $1.134M $1.134M
YoY Change 0.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.134M $1.134M
YoY Change 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.165M $13.83M
Total Long-Term Liabilities $1.134M $1.134M
Total Liabilities $3.299M $14.96M
YoY Change -77.95% 116.95%
SHAREHOLDERS EQUITY
Retained Earnings -$295.2M -$271.0M
YoY Change 8.92% 11.86%
Common Stock $250.8M
YoY Change 25084500.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $11.00K
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity $11.89M -$20.20M
YoY Change
Total Liabilities & Shareholders Equity $15.19M $18.73M
YoY Change -18.91% 73.27%

Cashflow Statement

Concept 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$5.206M -$8.754M
YoY Change -40.53% 14.55%
Depreciation, Depletion And Amortization $37.00K $74.00K
YoY Change -50.0% 15.63%
Cash From Operating Activities -$6.059M -$9.310M
YoY Change -34.92% -11.25%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$40.00K
YoY Change -75.0% 300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$40.00K
YoY Change -75.0% 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -2.575M 25.91M
YoY Change -109.94% 87.75%
NET CHANGE
Cash From Operating Activities -6.059M -9.310M
Cash From Investing Activities -10.00K -40.00K
Cash From Financing Activities -2.575M 25.91M
Net Change In Cash -8.644M 16.56M
YoY Change -152.2% 401.82%
FREE CASH FLOW
Cash From Operating Activities -$6.059M -$9.310M
Capital Expenditures -$10.00K -$40.00K
Free Cash Flow -$6.049M -$9.270M
YoY Change -34.75% -11.55%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y10M24D
us-gaap Cost Of Revenue
CostOfRevenue
2000
CY2021Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30801110
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-2274000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7476000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-1739000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2296000
CY2021Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.17
us-gaap Share Based Compensation
ShareBasedCompensation
661000
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-65000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-107000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
204000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-455000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-7149000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
538000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
366000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2220000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
366000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
659000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-202000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-729000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-692000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20155000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22265000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
32000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
291000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-32000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-291000
CY2020Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
3765000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32848000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
17000000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
32848000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
985000
vcnx Redemption Of Convertible Debt
RedemptionOfConvertibleDebt
8531000
vcnx Redemption Of Convertible Debt
RedemptionOfConvertibleDebt
108000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
985000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
598000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
18649000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
11475000
vcnx Proceeds From Issuance Of Convertible Debt Net Of Discount
ProceedsFromIssuanceOfConvertibleDebtNetOfDiscount
8000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
50000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
1134000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
us-gaap Interest Expense Debt
InterestExpenseDebt
113000
us-gaap Share Based Compensation
ShareBasedCompensation
388000
CY2021Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22781000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
128000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-5969000
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
16940000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
156000
CY2021Q3 us-gaap Profit Loss
ProfitLoss
-5206000
CY2021Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
11890000
us-gaap Profit Loss
ProfitLoss
-17749000
us-gaap Profit Loss
ProfitLoss
-22406000
us-gaap Depreciation
Depreciation
128000
us-gaap Depreciation
Depreciation
237000
us-gaap Interest Expense Debt
InterestExpenseDebt
458000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23332000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
36872000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3145000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14316000
vcnx Non Cash Capital Expenditures Incurred But Not Yet Paid
NonCashCapitalExpendituresIncurredButNotYetPaid
7000
vcnx Non Cash Capital Expenditures Incurred But Not Yet Paid
NonCashCapitalExpendituresIncurredButNotYetPaid
-161000
vcnx Offering Costs In Accrued Expenses
OfferingCostsInAccruedExpenses
15000
vcnx Offering Costs In Accounts Payable
OfferingCostsInAccountsPayable
100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20200000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10596000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2776000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22300000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-295200000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13741000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17092000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277500000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These condensed consolidated financial statements have been prepared in conformity with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of expenses during the reporting period. Such management estimates include those relating to assumptions used in the valuation of stock option awards, and valuation allowances against deferred income tax assets. Actual results could differ from those estimates. </p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Other Risks and Uncertainties </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. Cash equivalents are deposited in interest-bearing money market accounts. Although the Company deposits its cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. Management believes the financial risk associated with these balances is minimal and has not experienced any losses to date.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party manufacturers for the manufacture of drug substance and drug product for clinical trials. The Company also relies on certain third parties for its supply chain. Disputes with these third- party manufacturers or shortages in goods or services from third-party suppliers could delay the manufacturing of the Company’s product candidates and adversely impact its results of operations. </p>
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7335000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7296000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7008000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6880000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
327000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
416000
CY2021Q3 us-gaap Depreciation
Depreciation
37000
us-gaap Depreciation
Depreciation
128000
CY2020Q3 us-gaap Depreciation
Depreciation
74000
us-gaap Depreciation
Depreciation
237000
CY2021Q3 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
662000
CY2020Q4 vcnx Accrued Clinical Trial Cost Current
AccruedClinicalTrialCostCurrent
987000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
418000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
428000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
88000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
225000
CY2021Q3 vcnx Accrued Interest Current
AccruedInterestCurrent
16000
CY2020Q4 vcnx Accrued Interest Current
AccruedInterestCurrent
250000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1208000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1937000
CY2020Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
65000
CY2020Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
0
CY2021Q3 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
832868
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
126000
vcnx Royalty Payments Percent Of Net Sales
RoyaltyPaymentsPercentOfNetSales
0.01
CY2021Q3 vcnx Operating Lease Monthly Rental Payments
OperatingLeaseMonthlyRentalPayments
14000
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
43533
CY2021Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
145110
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
44000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
131000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
42000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
3566199
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
334088
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.83
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.58
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.28
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
156000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
388000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
661000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q3 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
vcnx Number Of Business Activity
NumberOfBusinessActivity
1
vcnx Number Of Segment Managers For Operations Or Operating Results
NumberOfSegmentManagersForOperationsOrOperatingResults
0
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
44000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
131000
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
42000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
126000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001

Files In Submission

Name View Source Status
0001564590-21-055065-index-headers.html Edgar Link pending
0001564590-21-055065-index.html Edgar Link pending
0001564590-21-055065.txt Edgar Link pending
0001564590-21-055065-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vcnx-10q_20210930.htm Edgar Link pending
vcnx-10q_20210930_htm.xml Edgar Link completed
vcnx-20210930.xsd Edgar Link pending
vcnx-20210930_cal.xml Edgar Link unprocessable
vcnx-20210930_def.xml Edgar Link unprocessable
vcnx-20210930_lab.xml Edgar Link unprocessable
vcnx-20210930_pre.xml Edgar Link unprocessable
vcnx-ex311_14.htm Edgar Link pending
vcnx-ex312_12.htm Edgar Link pending
vcnx-ex321_13.htm Edgar Link pending